Activating Gene Expression with Antigene RNAs to Treat Genetic Diseases

描述（由申请人提供）：常见的遗传性疾病肌肉萎缩症（MD），脊髓性肌萎缩症（SMA）和脆性X综合征（FXS）对儿童发育有严重影响。它们有一个共同的事实，即它们可以通过增加一种疾病相关基因的表达来潜在地治疗。然而，由于大多数药物的非特异性作用，基因表达的药理学激活通常不被认为是治疗治疗的一种选择。最近，科里实验室发现了一种强大而特异的方法来增加选定基因的表达。小的双工rna，称为抗原rna (agnas)，以基因启动子为目标，开启转录。这些agnas实际上与无所不在的非编码rna相互作用，这些非编码rna跨越基因启动子，引发局部染色质结构的变化，从而导致基因表达增加。MD、SMA和FXS的疾病相关基因都有与其基因启动子区域相关的非编码rna，并且它们的启动子定义明确，这是成功使用agnas的重要特征。拟议的研究将全面表征非编码RNA转录物跨越每个疾病相关基因的启动子。随后，将设计针对疾病相关基因启动子的agnas，并对其进行筛选，以确定那些能够激活基因表达的基因。最后，将研究agRNA介导的基因激活的关键特征，以了解agRNA的机制，并帮助建立有效的agRNA设计规则。这项研究的结果将为开发作为新型治疗药物的agnas奠定基础，最终治疗需要增加特定基因表达的衰弱性遗传疾病，如MD， SMA和FXS。肌肉萎缩症、脊髓性肌萎缩症和脆性X综合征只是扰乱儿童正常发育的许多衰弱性疾病中的几种，这些疾病导致生活质量下降，寿命大幅缩短。这些疾病的治疗往往依赖于增加特定基因的表达，而目前可用的药物无法做到这一点。这项研究的结果将为抗原rna作为潜在的基因特异性药物提供证据，并首次为许多需要特异性增加基因表达的疾病的治疗打开大门。

DESCRIPTION (provided by applicant): The common genetic diseases muscular dystrophy (MD), spinal muscular atrophy (SMA) and fragile X syndrome (FXS) have crippling effects on childhood development. They share in common the fact that they can potentially be treated by increasing expression of a single disease-related gene. However, pharmacological activation of gene expression is not typically considered an option for therapeutic treatments due to the non-specific effects of most drugs. Recently the Corey laboratory discovered a robust and specific method for increasing expression of select genes. Small duplex RNAs, called antigene RNAs (agRNAs), are targeted to gene promoters to turn on transcription. These agRNAs actually interact with ubiquitous non-coding RNAs that span gene promoters to elicit changes in local chromatin structure, thus resulting in increased gene expression. The disease-related genes for MD, SMA and FXS all have non- coding RNAs associated with their gene promoter regions and their promoters are well-defined, important features for the successful use of agRNAs. The proposed research will fully characterize non-coding RNA transcripts that span the promoter of each disease-related gene. agRNAs will then be designed to target disease-related gene promoters and screened to identify those that can activate gene expression. Finally, key features of agRNA-mediated gene activation will be investigated to understand agRNA mechanism and help establish efficient agRNA design rules. The results of this study will lay the groundwork for developing agRNAs as novel therapeutic agents to ultimately treat debilitating genetic diseases like MD, SMA and FXS that require increased expression of specific genes. Muscular dystrophy, spinal muscular atrophy and fragile X syndrome are just a few of the many debilitating disorders that disrupt proper childhood development, resulting in a poor quality of life and dramatically shortened lifespans. Treatments for these diseases often lie in increasing the expression of select genes, which is not an option with currently available drugs. The results from this proposed research will provide evidence for antigene RNAs as potential gene-specific drugs and open the door for the first time to treatments for many diseases that require specific increases in gene expression.